BerandaNCYT • LON
add
Novacyt SA
Tutup sebelumnya
GBX 51,00
Rentang hari
GBX 48,50 - GBX 50,00
Rentang tahun
GBX 39,07 - GBX 86,00
Kapitalisasi pasar
40,37 jt EUR
Volume Rata-Rata
227,42 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
EPA
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(GBP) | Des 2023info | Perubahan Y/Y |
---|---|---|
Pendapatan | 4,12 jt | 81,82% |
Biaya operasional | 12,52 jt | 48,31% |
Laba bersih | -9,97 jt | -17,10% |
Margin laba bersih | -242,04 | 35,59% |
Penghasilan per saham | — | — |
EBITDA | -7,10 jt | -41,10% |
Tarif pajak efektif | 2,93% | — |
Neraca
Total aset
Total liabilitas
(GBP) | Des 2023info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 44,06 jt | -49,34% |
Total aset | 133,82 jt | -5,03% |
Total liabilitas | 46,57 jt | 81,32% |
Total ekuitas | 87,24 jt | — |
Saham yang beredar | 70,63 jt | — |
Harga terhadap reservasi | 0,41 | — |
Tingkat pengembalian aset | -21,46% | — |
Pengembalian modal | -28,44% | — |
Arus Kas
Perubahan bersih tunai
(GBP) | Des 2023info | Perubahan Y/Y |
---|---|---|
Laba bersih | -9,97 jt | -17,10% |
Kas dari operasi | -9,65 jt | -59,94% |
Tunai dari investasi | -7,47 jt | -3.853,70% |
Tunai dari pembiayaan | -1,72 jt | -1.360,85% |
Perubahan bersih tunai | -18,84 jt | -197,44% |
Arus kas bebas | -3,81 jt | -56,02% |
Tentang
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Didirikan
2006
Situs
Karyawan
237